2024
Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk
Bergmark B, Marston N, Prohaska T, Alexander V, Zimerman A, Moura F, Murphy S, Goodrich E, Zhang S, Gaudet D, Karwatowska-Prokopczuk E, Tsimikas S, Giugliano R, Sabatine M. Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk. New England Journal Of Medicine 2024, 390: 1770-1780. PMID: 38587249, DOI: 10.1056/nejmoa2402309.Peer-Reviewed Original ResearchConceptsNon-HDL cholesterolElevated cardiovascular riskLevels of triglyceridesTriglyceride levelsCardiovascular riskModerate hypertriglyceridemiaApolipoprotein BAdverse eventsNon-high-density lipoprotein (HDL) cholesterolLow-density lipoprotein (LDL) cholesterolBaseline to 6 monthsMedian triglyceride levelsRisk of adverse eventsLDL cholesterol levelsHigh cardiovascular riskTriglyceride-rich lipoproteinsApolipoprotein C-IIISevere hypertriglyceridemiaMedian ageTriglyceride loweringPlatelet abnormalitiesNo significant changesPlaceboPhase 2bPrimary outcome
2022
Effects of dapagliflozin on cardiovascular and kidney events by baseline eGFR and UACR in patients with type 2 diabetes mellitus: a patient-level pooled analysis of DECLARE-TIMI 58 and DAPA-CKD trials
Moura F, Wiviott S, Chertow G, Dwyer J, Gause-Nilsson I, Johansson P, Langkilde A, McMurray J, Mosenzon O, Raz I, Rossing P, Wheeler D, Sabatine M, Heerspink H. Effects of dapagliflozin on cardiovascular and kidney events by baseline eGFR and UACR in patients with type 2 diabetes mellitus: a patient-level pooled analysis of DECLARE-TIMI 58 and DAPA-CKD trials. European Heart Journal 2022, 43: ehac544.2407. DOI: 10.1093/eurheartj/ehac544.2407.Peer-Reviewed Original ResearchUrinary albumin:creatinine ratioEffects of dapagliflozinSodium-glucose co-transporter 2Kidney eventsType 2 diabetes mellitusDAPA-CKD trialKidney endpointsBaseline eGFRAbsolute rate differenceDAPA-CKDKidney functionHigh urinary albumin:creatinine ratioPatient yearsPooled analysisPatients type 2 diabetes mellitusCardiovascular deathSubgroups of baseline eGFRPatient-level pooled analysisAlbumin:creatinine ratioLevel of kidney functionFollow-up timeCategories of eGFRBaseline kidney functionHigh cardiovascular riskAbsolute risk reduction